

**BUY****TP: Rs 1,013 | ▲ 25%****ALEMBIC PHARMA**

| Pharmaceuticals

| 05 February 2026

## Domestic business expected to recover from FY27

- Sales/EBITDA/PAT were 0.5%/-5.8%/-24.6% below our estimates due to 5% higher RM cost. APAT was 1.2% below our estimates**
- Domestic sales to pick from 1QFY27 and growth likely to report at par with the IPM with the aid of internal restructuring**
- Lower EBITDA margin led to reduction in EPS by 17%/10%6% for FY26/27E&28E. Reduce ascribed PE to 21 to arrive at a PT of Rs 1013**

**Foram Parekh**  
**Research Analyst**  
 research@bobcaps.in

**Earnings below Estimates** – Sales grew by 10.8% YoY to Rs 18.7 bn, primarily driven by 35.8% YoY growth in the RoW region, 6.2% YoY growth in the India region, and 6.1% YoY growth in the US region to Rs 5.5 bn. Healthy growth from international markets (generic portfolio) resulted in a 223bps contraction in gross margin to 71.8%. Operating leverage played out during the quarter, with other expenses (excluding R&D) contributing 24% of sales in 3QFY26 versus 27% in 3QFY25, leading to a 27bps decline in EBITDA margin to 15.6%. During the quarter, there was an exceptional cost of Rs 422 mn attributed to a one-time labour code expense, resulting in a 3.9% YoY decline in PAT to Rs 1.3 bn. Adjusting for the one-time cost, PAT grew by 28% YoY to Rs 1.7 bn.

**Domestic growth likely to pick up in 1QFY27E** – India region reported growth 1% above our estimates to Rs 6.5bn. The growth was driven by 22% YoY growth in the Animal health segment and 3% YoY growth in the Specialty segment which was offset by 1% decline in the Acute segment. The company expects domestic sales to recover from 1QFY27 through internal measures; thus, we expect domestic sales to grow at a CAGR of 9%, at par with the IPM, from FY26-28E to Rs 29.6bn in FY28E.

**US sales growth to be driven by new launches** – US sales reported 4% below our estimates to Rs 5.5 bn. The growth was muted due to price erosion in the US generics. The company expects to launch its first specialty brand Pivya in 4QFY26, whose full year impact is expected in FY27E, with a scale up over 12-18 months from launch. The company continues to spend 8-9% of its sales on R&D, thus cumulatively have 23 ANDA approvals and expects to launch 4-5 products in 4QFY26. Overall, we expect US sales to grow at a CAGR of 11% from FY26-28E.

**Our View** – As Earnings were lower than estimates on operational front followed by muted 4QFY26 earnings (Q2&Q3 stronger for acute), EBITDA Margin for FY26 is expected to report ~15.8% (9MFY26 reported at 16.2%). Hence, we reduce EPS for FY26/27E/28E by 17%/10% and 6% respectively. Proportionately, we reduce our ascribe PE to 21x (earlier 23x) and roll forward to Dec'27 EPS to arrive at a PT of Rs 1013, implying 25% upside on the stock, thus maintaining BUY on the stock.

## Key changes

	Target	Rating
▼	◀ ▶	

Ticker/Price	ALPM IN/Rs 810
Market cap	US\$ 1.8bn
Free float	31%
3M ADV	US\$ 1.3mn
52wk high/low	Rs 1,108/Rs 725
Promoter/FPI/DII	70%/5%/13%

Source: NSE | Price as of 5 Feb 2026

## Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	66,721	73,338	81,438
EBITDA (Rs mn)	10,082	11,554	13,595
Adj. net profit (Rs mn)	5,697	6,417	7,963
Adj. EPS (Rs)	29.0	32.6	40.5
Consensus EPS (Rs)	29.0	35.9	45.2
Adj. ROAE (%)	11.8	12.3	14.0
Adj. P/E (x)	27.9	24.8	20.0
EV/EBITDA (x)	15.0	12.9	11.2
Adj. EPS growth (%)	(7.4)	12.5	24.1

Source: Company, Bloomberg, BOBCAPS Research

## Stock performance



Source: NSE



## Financial Highlights

**Fig 1 – Quarterly snapshot**

(Rs mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	Var (%)
Net Sales	18,763	16,927	10.8	19,102	(1.8)	18,667	0.5
Total Expenses	15,828	14,325	10.5	15,945	(0.7)	15,549	1.8
(%) of net sales	84	85		83		83	
Raw material consumed	5,290	4,395	20.3	5,159	2.5	5,040	5.0
(%) of net sales	28	26		27		27	
Staff cost	4,327	3,975	8.9	4,375	(1.1)	4,387	(1.4)
(%) of net sales	23	23		23		24	
R&D cost	1,650	1,354	21.8	1,870	(11.8)	1,680	(1.8)
(%) of net sales	9	8		10		9	
SG&A	4,561	4,600	(0.9)	4,540	0.5	4,443	2.7
(%) of net sales	24	27		24		24	
EBITDA	2,935	2,602	12.8	3,157	(7.0)	3,117	(5.8)
PBT	2,056	1,774	15.9	2,223	(7.5)	2,147	(4.3)
Less: Taxation	295	401		400		408	
Recurring PAT	1,760	1,373	28.2	1,823	(3.4)	1,739	1.2
Less: Minority Interest	8	(11)		(24)		(24)	
Exceptional items	(422)	0		0		0	
PAT attributable to shareholders	1,330	1,384	(3.9)	1,847	(28.0)	1,764	(24.6)
<b>Key Ratios (%)</b>							
Gross Margin	71.8	74.0	(223)	73.0	(118.264)	73.0	(119)
EBITDA Margin	15.6	15.4	27	16.5	(88.457)	16.7	(106)
Tax / PBT	14.4	22.6	(822)	18.0	(362.39)	19.0	(463)
NPM	9.4	8.1	127	9.5	(16.2041)	9.3	6
EPS	9.0	7.0	28.2	9.3	(3.4)	8.8	1.2

Source: Company, BOBCAPS Research


**Fig 2 – Revenue Mix**

(Rs mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	Var (%)
Formulations	16,110	14,340	12.3	15,970	0.9	15,766	2
India	6,520	6,140	6.2	6,390	2.0	6,447	1
US	5,530	5,210	6.1	5,660	(2.3)	5,731	(4)
ROW	4,060	2,990	35.8	3,920	3.6	3,588	13
API	2,640	2,590	1.9	3,140	(15.9)	2,901	(9)
Net Sales	18,750	16,930	10.8	19,110	(1.9)	18,667	0

Source: Company, BOBCAPS Research


## Financial Charts

**Fig 3 – Domestic sales growth driven by animal health segment**




Source: Company, BOBCAPS Research

**Fig 4 – US sales growth lowered due to pricing pressure in generics portfolio**




Source: Company, BOBCAPS Research

**Fig 5 – Sales growth increased YoY primarily due to RoW region**




Source: Company, BOBCAPS Research

**Fig 6 – EBITDA growth aided by operational leverage**




Source: Company, BOBCAPS Research

**Fig 7 – Margins lowered due to lower sales in branded domestic business**



Source: Company, BOBCAPS Research

**Fig 8 – APAT growth driven by healthy operations**



Source: Company, BOBCAPS Research

## Earnings Call highlights

### Outlook

- Recent **out-licensing and manufacturing agreements** are expected to support scaling of **injectable and oncology facilities**, driving higher utilization over the **next 12–18 months**.
- **Pivya launch in the US targeted for Q4 FY26 (Feb'26)**; while near-term profitability may be impacted, management expects **market share gain over 12–18 months**, underpinning a strong **medium-to-long-term opportunity**.
- India Branded business aims for growth alignment with the market by Q1FY27 via improved operational execution & Launches.
- US Market expected to grow 10-12% on a full year basis, targets mid-teen growth (10%-15%) for FY27 and FY28.

### Financial Highlights

- **Revenue:** Q3 revenue up 11% YoY to Rs 1,876 Cr, driven by volumes expansion, new launches and increased attraction in ex-US markets, partially offset by US pricing pressure.
- **Gross margin:** 72%, lower YoY due to product mix and pricing challenges, but comfortably within 70–75% target range, aided by cost efficiency initiatives in international business.
- **EBITDA (pre R&D):** stood at Rs 464 cr, 25% of revenue vs 23% last year, reflecting improved operating leverage & prudent management of discretionary spending. (20% YoY Growth).
- **R&D investments:** R&D spend up 33% YoY to ₹165 Cr, aligned with full-year guidance of Rs 600- 650 Cr; R&D at ~9% of revenue, expected to sustain in between 8-9% in FY26, focused on complex injectables, peptides, oral solids and drug discovery with emphasis on early entry opportunities.
- **Other Income~** Rs 15.5 Cr comprising the forex gain.
- **PBT:** PBT up 15% YoY to Rs205 Cr and PAT (pre-exceptional) up 21% YoY, despite pricing headwinds.
- **Exceptional item:** One-time Rs 42 Cr labour code provision impacted reported PAT but no operational or cash flow impact.
- **Balance sheet:** Net debt reduced to Rs 1,213 Cr, working capital ~ Rs 2944 Cr.
- **9M FY26 performance robust:** Revenue up 12% YoY to Rs 5500 Cr, EBITDA margin is 25% (pre-R&D) and 17% (Post R&D); PAT (pre-exceptional) grew ~22%, indicating consistent execution.

## India Branded Business

- **Revenue:** 6% YoY growth to Rs 625 Cr , led by accelerating momentum in **Gynecology, Ophthalmology and Animal Health** segments.
- **Anti-infective:** Anti-infective portfolio grew in line, supported by **4 new product launches** during the quarter.
- **Underperformance (Vs Market):** Not led by underinvestment, but over-conservatism on doctor spend (UCPMP Sensitivity) and Normalization after COVID-led Brand bump, with management focusing on fixing the fundamental issues.

## International Business

- **Strong global momentum:** driven by 36% YoY growth in RoW markets, reflecting strategic geographic expansion and focused execution.
- **US business:** grew 6% YoY, aided by higher volumes and recent launches, despite ongoing pricing pressure, with meaningful acceleration expected over the next ~2 years as injectable and complex product approvals come through, building on Alembic's strong base market share and leadership in select molecules. Margin expansion would be cushion for expenses come from Pivya.
- **Pipeline progress (US):** 1 ANDA filed in Q3; **270 cumulative filings and 232 Cumulative approvals inclusive of 20 tentative approvals.** In Q3, Received **7 US approvals**, launched **2 products**, with **4–5 additional launches expected in Q4.**
- **Pivya launch:** On track for launch, MR onboarded and material shipped to US, strengthens US franchise, first-line oral antibiotic targeting uncomplicated UTI in women with a track record of low treatment & emergent adverse events.
- **Pivya Positioning:** Pivya has been positioned as an incremental branded business with success defined relatively to capital-light licensing economics and manageable Royalty outgo and reimbursement discussions outgoing.
- **Competitive Positioning:** Pivya sits in a “sweet spot” on efficacy, between high-cost newer AMR therapies and older genericized options, enabling differentiated positioning in the UTI segment.
- **Pricing headwinds:** persist in US and API segments, but **cost efficiency programs continue to cushion margin impact.**

## Valuation methodology

As Earnings were lower than estimates on operational front followed by muted 4QFY26 earnings (Q2&Q3 stronger for acute), EBITDA Margin for FY26 is expected to report ~15.8% (9MFY26 reported at 16.2%). Hence, we reduce EPS for FY26/27E/28E by 17%/10% and 6% respectively. Proportionately, we reduce, our ascribe PE to 21x (earlier 23x) and roll forward to Dec'27 EPS to arrive at a PT of Rs 1013 (earlier PT Rs 1136) implying 25% upside on the stock, thus maintaining BUY on the stock.

**Fig 9 – Change in Estimates**

(Rs mn)	New			Old			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Sales	73,338	81,438	89,472	73,338	81,438	89,472	(0.0)	0.0	(0.0)
EBITDA	11,554	13,595	16,191	12,289	14,410	16,638	(6.0)	(5.7)	(2.7)
EBITDA margin (%)	15.8	16.7	18.1	16.8	17.7	18.6	(100bps)	(100bps)	(50bps)
PAT	5,995	7,963	9,989	7,261.0	8,837.0	10581	(17.4)	(9.9)	(5.6)
EPS (Rs)	30.5	40.5	50.8	36.9	45	53.8	(17.3)	(10.0)	(5.5)







Source: Company, BOBCAPS Research

## Key risks

Key downside risks to our estimates are:

- Adverse action on manufacturing facilities catering to the US
- Slow pace of new approvals/launches

## Valuation Bands

**Fig 10 – PE Band**

**Fig 11 – EV/EBITDA Band**

**Fig 12 – P/BV Band**

**Fig 13 – P/BV Band**

**Fig 14 – Alembic vs Nifty Pharma**

**Fig 15 – Alembic vs Nifty 50**


## Financials

### Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
<b>Total revenue</b>	<b>62,290</b>	<b>66,721</b>	<b>73,338</b>	<b>81,438</b>	<b>89,472</b>
EBITDA	9,337	10,082	11,554	13,595	16,191
Depreciation	2,727	2,786	3,216	3,521	3,838
EBIT	6,611	7,297	8,337	10,073	12,353
Net interest inc./exp.)	(562)	(788)	(962)	(713)	(570)
Other inc./exp.)	283	426	450	350	400
Exceptional items	0	0	0	0	0
EBT	6,332	6,934	7,825	9,710	12,182
Income taxes	160	1,252	1,409	1,748	2,193
Extraordinary items	0	(8)	(422)	0	0
Min. int./Inc. from assoc.	0	(14)	0	0	0
<b>Reported net profit</b>	<b>6,172</b>	<b>5,688</b>	<b>5,995</b>	<b>7,963</b>	<b>9,989</b>
Adjustments	0	(8)	(422)	0	0
<b>Adjusted net profit</b>	<b>6,172</b>	<b>5,697</b>	<b>6,417</b>	<b>7,963</b>	<b>9,989</b>

### Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	7,356	8,799	9,444	10,263	11,276
Other current liabilities	2,038	2,358	2,200	814	895
Provisions	1,748	2,102	2,310	2,565	2,818
Debt funds	5,132	12,575	8,803	7,042	5,634
Other liabilities	0	0	0	0	0
Equity capital	393	393	393	393	393
Reserves & surplus	46,093	49,842	53,674	59,475	67,302
Shareholders' fund	46,486	50,235	54,067	59,868	67,695
<b>Total liab. and equities</b>	<b>62,759</b>	<b>76,069</b>	<b>76,824</b>	<b>80,553</b>	<b>88,318</b>
Cash and cash eq.	1,266	901	680	(229)	2,318
Accounts receivables	10,248	13,998	15,069	16,734	18,385
Inventories	16,435	22,881	22,102	22,312	24,513
Other current assets	3,169	3,409	2,934	4,886	5,368
Investments	930	1,272	1,272	1,272	1,272
Net fixed assets	25,467	25,235	26,395	27,206	28,090
CWIP	5,244	8,372	8,372	8,372	8,372
Intangible assets	0	0	0	0	0
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
<b>Total assets</b>	<b>62,759</b>	<b>76,069</b>	<b>76,824</b>	<b>80,553</b>	<b>88,318</b>

### Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
<b>Cash flow from operations</b>	<b>8,651</b>	<b>952</b>	<b>11,052</b>	<b>8,059</b>	<b>11,410</b>
Capital expenditures	(3,450)	(5,636)	(4,376)	(4,332)	(4,722)
Change in investments	33	(342)	0	0	0
Other investing cash flows	0	0	0	0	0
<b>Cash flow from investing</b>	<b>(3,417)</b>	<b>(5,978)</b>	<b>(4,376)</b>	<b>(4,332)</b>	<b>(4,722)</b>
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	(2,089)	7,443	(3,773)	(1,761)	(1,408)
Interest expenses	(562)	(788)	(962)	(713)	(570)
Dividends paid	(2,162)	(2,162)	(2,162)	(2,162)	(2,162)
Other financing cash flows	21	168	0	0	0
<b>Cash flow from financing</b>	<b>(4,792)</b>	<b>4,662</b>	<b>(6,897)</b>	<b>(4,636)</b>	<b>(4,141)</b>
Chg in cash & cash eq.	443	(365)	(221)	(909)	2,547
<b>Closing cash &amp; cash eq.</b>	<b>1,266</b>	<b>901</b>	<b>680</b>	<b>(229)</b>	<b>2,318</b>

### Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	31.4	29.0	30.5	40.5	50.8
Adjusted EPS	31.4	29.0	32.6	40.5	50.8
Dividend per share	11.0	11.0	11.0	11.0	11.0
Book value per share	236.5	255.6	275.1	304.6	344.4

### Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	2.5	2.3	2.0	1.9	1.7
EV/EBITDA	16.5	15.0	12.9	11.2	9.5
Adjusted P/E	25.9	27.9	24.8	20.0	15.9
P/BV	3.4	3.2	2.9	2.7	2.4

### DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	97.5	82.2	82.0	82.0	82.0
Interest burden (PBT/EBIT)	95.8	95.0	93.9	96.4	98.6
EBIT margin (EBIT/Revenue)	10.6	10.9	11.4	12.4	13.8
Asset turnover (Rev./Avg TA)	30.7	29.2	29.2	31.4	31.9
Leverage (Avg TA/Avg Equity)	1.1	1.2	1.2	1.1	1.1
Adjusted ROAE	13.9	11.8	12.3	14.0	15.7

### Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	10.2	7.1	9.9	11.0	9.9
EBITDA	31.8	8.0	14.6	17.7	19.1
Adjusted EPS	80.2	(7.4)	12.5	24.1	25.5
Profitability & Return ratios (%)					
EBITDA margin	15.0	15.1	15.8	16.7	18.1
EBIT margin	10.6	10.9	11.4	12.4	13.8
Adjusted profit margin	9.9	8.5	8.7	9.8	11.2
Adjusted ROAE	13.9	11.8	12.3	14.0	15.7
ROCE	13.6	13.5	14.0	16.1	18.2
Working capital days (days)					
Receivables	60	77	75	75	75
Inventory	96	125	110	100	100
Payables	43	48	47	46	46
Ratios (x)					
Gross asset turnover	1.6	1.5	1.5	1.6	1.6
Current ratio	2.8	3.1	2.9	3.2	3.4
Net interest coverage ratio	11.8	9.3	8.7	14.1	21.7
Adjusted debt/equity	0.1	0.2	0.2	0.1	0.0

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 01 February 2030

Brand Name: **BOBCAPS**

Trade Name: [www.barodaetrade.com](http://www.barodaetrade.com)

CIN: U65999MH1996GOI098009

Logo:  TRUST | INNOVATION | EXCELLENCE

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

**Recommendation scale: Recommendations and Absolute returns (%) over 12 months**

**BUY** – Expected return >+15%


**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Ratings and Target Price (3-year history): ALEMBIC PHARMA (ALPM IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

#### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### **Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014**

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### **Other disclaimers**

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### **Distribution into the United Kingdom ("UK"):**

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### **No distribution into the US:**

This report will not be distributed in the US and no US person may rely on this communication.

#### **Other jurisdictions:**

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.